Document is current
Any future updates will be listed below
-
Authors
Almstedt, K. https://orcid.org/0000-0002-4600-2410
Mendoza, S.
Otto, M.
Battista, M. J.
Steetskamp, J.
Heimes, A. S.
Krajnak, S.
Poplawski, A.
Gerhold-Ay, A.
Hasenburg, A.
Denkert, C.
Schmidt, M.
- License Information
-
More Information
Article History
Received: 30 March 2020
Accepted: 11 May 2020
First Online: 20 May 2020
Compliance with ethical standards
:
: K. Almstedt received speaker honoraria from Roche Pharma AG, Pfizer Pharma GmbH and AstraZeneca. M. Schmidt received honoraria for speaker or consultancy role from AMGEN, AstraZeneca, Eisai, Lilly, Myelo Therapeutics, Novartis, Pantarhei Bioscience, Pfizer, and Roche. He received research funding from AstraZeneca, BioNTech, Eisai, Genentech, Myelo Therapeutics, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, and Roche. He received travel reimbursement from Pfizer and Roche. M. Otto received honoraria for speaker or consultancy role from AstraZeneca, Boehringer-Ingelheim, Roche and Sividon. He received travel reimbursement from AstraZeneca, and Boehringer-Ingelheim. MJ. Battista received honoraria for speaker or consultancy role from AstraZenca, MSD, PharmaMar, Roche Pharma AG, TEVA, Tesaro. He received travel reimbursement from Celgene, PharmaMar and Pierre Fabre. S. Krajnak received speaker honoraria from Roche. He received research funding from Novartis. He received travel reimbursement from PharmaMar. A. Hasenburg received honoraria from AstraZeneca, Celegen, MedConcept Gm, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Pierre Fabre, Softconsult, Roche Pharma AG, Streamedup!GmbH and Tesaro Bio Germany GmbH. She is a member of the advisory board of PharmaMar, Promedicis GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG and Tesaro Bio Germany GmbH. She received research funding from Celgene. C. Denkert has been cofounder and shareholder of Sividon Diagnostics (now Myriad), has received speaker honoraria from Teva, Novartis, Pfizer, Roche, Amgen and has been consultant for MSD Oncology, Amgen, Roche and Daiichi-Sankyo. All other authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
